Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.336 | Prospective Study on Sessile Serrated Adenoma/Polyps in the Colorectum | Dr. LUI Abdul Rashid N.S. |
| 2022.431 | A Phase II/III, Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients with Moderate to Severe COVID-19 |
Dr. LUI Grace Chung Yan 雷頌恩 |
| 2009.466 | Prospective and controlled study on medial arch suppport in long distance running, comparing flat insole and tailor made medial arch support insole, by plantar pressure distribution and lower limb electromyogram | Mr LUE BO KONG |
| 2016.583 | Comparison of the pre-exercise ingestion effect between whey PRO and alpha-lactalbumin on substrate metabolism, muscle damage, affective responses and subsequence exercise performance |
Ms. LU Qin 覃璐 |
| 2016.381 | Comparison of the Role of Whey Protein and Alpha-lactalbumin in Recovery of Muscle Damage, Muscle Soreness and Affective Responses after Strenuous Prolonged Endurance Exercise |
Ms. LU Qin 覃璐 |
| 2014.388 | Observational study on risk factors of recurrence after breast-conserving surgery for Chinese early-stage breast cancer patients | Miss LU Qianyun |
| 2015.625 | Objective ways to assess the fetal facial profile features using 2D and 3D ultrasound |
Ms. LU Jing 路晶 |
| 2017.644 | Pitfalls in assessing chorioamnionicity: novel observations and literature review |
Ms. LU Jing 路晶 |
| 2023.496 | Hong Kong Cohort of Abnormal Sleep in Ageing Population (HK-ASAP): an observational study on sleep quality, brain reserve and cognitive phenotypes in community-dwelling older adults | Dr. LU Hanna |
| 2023.074 | A pilot randomized controlled trial of MRI-informed high-frequency transcranial random noise stimulation (hf-tRNS) for sleep disturbance and cognitive dysfunction in mild vascular cognitive impairment | Dr. LU Hanna |
| 2021.658 | Development of a personalized turn-key solution to evaluate the treatment outcomes and adverse effects of slow-oscillatory transcranial direct current stimulation (so-tDCS) in elderly with subjective cognitive complaints | Dr. LU Hanna |
| 2023.171 | Simulation-informed modelling and personalized evaluation (SIMPLE): An MRI-based brain age matrices for predicting cognitive maintenance and healthy longevity | Dr. LU Hanna |
| 2023.636 | A pilot randomized controlled trial of MRI-guided focused low-intensity transcranial ultrasound stimulation (TUS) for sleep disturbances in patients with chronic tinnitus | Dr. LU Hanna |
| 2020.488 | Decoding the cognitive trajectory of Hong Kong SuperAgers: a six-year follow-up study | Dr. LU Hanna |
| 2020.631 | Gamma-band high-definition transcranial alternating current stimulation (HD-tACS) for sleep disturbances in mild neurocognitive disorders due to Alzheimer’s disease | Dr. LU Hanna |
| 2014.048 | Would attention network function differentiate between healthy aging and mild neurocognitive disorder due to Alzheimer's disease (MND-AD)? | Ms Lu Hanna |
| 2011.116 | A primate-specific miR-637 induces mesenchymal stem cell neural differentiation through RES corepressors | Prof. Lu Gang |
| 2013.169 | Study of genetic variations in predictive biomarkers of Parkinson | Prof. Lu Gang |
| 2013.216 | Characterization of MicroRNA-mediated neuronal differentiation of Mesenchymal Stem Cells for Axonal Regeneration | Prof. Lu Gang |
| 2012.094 | Characterization of MicroRNA-mediated neuronal differentiation of Mesenchymal Stem Cells for Axonal Regeneration | Prof. Lu Gang |
| 2014.430 | A prospective cohort study on the effectiveness of psychological preparation conducted by Hospital Play Specialist in reducing need of sedation and level of anxiety in paediatric patients who undergo MRI | Ms LOY Tammy Sze wah |
| 2012.155 | Effects of an interactive eLearning Information Package (eLIP) for hospitalized older people and families to make decisions about discharge locations: A non-equivalent control group pretest and postetest design | Ms LOW Lisa P.L. |
| 2010.151 | A novel approach for the non-invasive prenatal diagnosis of sex-linked disorders | Ms LOW Lisa P. L. |
| 2014.580 | Randomized Controlled Trial on the Effectiveness of Ayres Sensory Integration Approach using by Occupational Therapist for School-aged Children with Sensory Processing Deficits | Ms. LOUIE Frances Tsui Man |
| 2024.397 | Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | Dr. LOONG Ho Fung Herbert |
| 2024.347 | Cross-cultural adaptation and validation of the Oxford dyspnoea word cue set for stimulation of emotional processing in lung cancer patients | Dr. LOONG Ho Fung Herbert |
| 2019.477 | A Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | Dr. LOONG Herbert Ho-fung |
| 2020.567 | A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.022 | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.296 | A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer | Dr. LOONG Herbert Ho Fung |
| 2019.524 | Bayer 20810 - A Phase 1/2 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: LOXO-EXT-17005 - A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers | Dr. LOONG Herbert Ho Fung |
| 2019.159 | A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.541 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.040 | A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.554 | A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.375 | Prospective Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.453 | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.366 | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.457 | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.565 | A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.022 | Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients? |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.056 | LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.346 | Co-morbidities, healthcare utilization and survival outcomes of patients with soft-tissue and bone sarcomas in Hong Kong |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.658 | A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction |
Dr. LOONG Herbert Ho Fung 龍浩鋒 醫生 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2019.376 | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.493 | A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Dr. LOONG Herbert Ho Fung |
| 2019.386 | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms | Dr. LOONG Herbert Ho Fung |
| 2020.198 | Clinical Application of a Personalized Circulating Tumour DNA (ctDNA) Assay for Early Detection of Cancer Relapse |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
Page 99 of 254.